Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab

Patricia Muñoz-Villegas,1 Alejandra Sanchez-Rios,1 Mayra G Quinonez-Alvarado,2 Oscar Olvera-Montaño,1 Juan D Quintana-Hau,2 Leopoldo Baiza-Duran1 1Medical Affairs Department, Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, México; 2Research and Development Depar...

Full description

Bibliographic Details
Main Authors: Muñoz-Villegas P, Sanchez-Rios A, Quinonez-Alvarado MG, Olvera-Montaño O, Quintana-Hau JD, Baiza-Duran L
Format: Article
Language:English
Published: Dove Medical Press 2021-05-01
Series:Journal of Experimental Pharmacology
Subjects:
bevacizumab
pharmacokinetics
ranibizumab
safety
vascular endothelial growth factor
Online Access:https://www.dovepress.com/pharmacokinetics-and-safety-of-an-intravitreal-humanized-anti-vegf-a-m-peer-reviewed-fulltext-article-JEP

Internet

https://www.dovepress.com/pharmacokinetics-and-safety-of-an-intravitreal-humanized-anti-vegf-a-m-peer-reviewed-fulltext-article-JEP

Similar Items